STL Index for: Wilson Janice

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy". Adverse effects of such treatments are thought to be less severe, but can still be significant.

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Off-label use of rituximab, indications, side-effects, and dosing are some of the topics discussed.